Administrative costs of prior authorizations for glucagon-like peptide-1 agonists

Key Points

• The aim is to examine the administrative costs associated with prior authorizations for GLP-1 agonists, particularly focusing on weight loss prescriptions.
• Compared total hands-on time for GLP-1 agonists for weight loss and diabetes
• Assessed approval rates for prior authorizations
• Analyzed costs associated with the prior authorizations
• GLP-1 agonists for weight loss required significantly more hands-on time than those prescribed for diabetes.
• Approval rates for weight loss GLP-1 agonists were notably lower.
• Costs per prior authorization were higher for weight loss medications.